Skip to content
value.today

Scribe Therapeutics Inc.

SCTX
$330 Mmarket cap on Oct 30, 2026
Compare
World rank
#14,382
Revenue
—
annual
Net income
—
Employees
—

Scribe Therapeutics Inc. in brief

Scribe Therapeutics Inc. is a listed company in the Biotechnology industry, based in Alameda, California, USA. Its market value was $330 M on 30 October 2026, which makes it the 14,382nd largest listed company in the world and the 2,815th largest in the USA on this site. Benjamin L. Oakes is its chief executive. Its shares trade under the symbol SCTX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Scribe Therapeutics Inc. timeline

2 events, 2021–2026
  1. 2021
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2026
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 27 July 2026; shares registered for exchange trading on 21 July 2026.

Events of Scribe Therapeutics Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$98 M$195 M$293 M$391 M

World rank over time

▼ down 621 places since 2026
2026-08-01: #13793#13,79320262026-10-14: #14061#14,06120262026-10-30: #14414#14,4142026

Rank in USA: #2,788 (Aug 2026) · #2,738 (Oct 2026) · #2,819 (Oct 2026)

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Mar 2025: revenue —, net income $-3M—Mar ’25Three months to Jun 2025: revenue $5M, net income $-10M$5MJun ’25Three months to Sep 2025: revenue $20M, net income $1M$20MSep ’25Three months to Mar 2026: revenue —, net income $-17M—Mar ’26Three months to Jun 2026: revenue $2M, net income $-6M$2MJun ’26Three months to Sep 2026: revenue $2M, net income $-10M$2MSep ’26

Latest quarter to Sep 2026: revenue $2M (-91.8% on a year earlier), net income $-10M.

SEC filings

Official filings of Scribe Therapeutics Inc. with the US Securities and Exchange Commission.

Balance sheet

Total assets
$78 M
Total liabilities
$101 M
Total equity
$-143 M

As of December-2025

Top 63 institutional investors in Scribe Therapeutics Inc.#

As of Sep 30, 2026
63 institutions held 16.2 M shares (about 85.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 69.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Scribe Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1a16z Capital Management, L.L.C.3,082,725New16.28%$57 MNov 16, 2026
2Avoro Capital Advisors LLC2,598,973New13.73%$48 MNov 16, 2026
3Ra Capital Management, L.P.1,802,178New9.52%$33 MNov 16, 2026
4Orbimed Advisors LLC1,348,825New7.12%$25 MNov 16, 2026
5Perceptive Advisors LLC920,341New4.86%$17 MNov 16, 2026
6ARK Investment Management LLC786,921New4.16%$14 MNov 13, 2026
7Baker Bros. Advisors LP688,691New3.64%$13 MNov 16, 2026
8Price T Rowe Associates Inc /MD/684,706New3.62%$13 MNov 16, 2026
9BlackRock, Inc.679,786New3.59%$13 MNov 13, 2026
10Sanofi500,000New2.64%$9 MNov 5, 2026
11Vanguard Capital Management LLC407,630New2.15%$8 MNov 13, 2026
12Franklin Templeton Inc380,019New2.01%$7 MNov 12, 2026
13Farallon Capital Management, L.L.C.380,000New2.01%$7 MNov 16, 2026
14Adage Capital Partners GP, L.L.C.380,000New2.01%$7 MNov 16, 2026
15Geode Capital Management, LLC245,412New1.30%$5 MNov 6, 2026
16State Street Corp171,147New0.90%$3 MNov 12, 2026
17Alyeska Investment Group, L.P.150,000New0.79%$3 MNov 16, 2026
18Menlo Ventures Management, L.P.97,690New0.52%$2 MNov 6, 2026
19TD Asset Management Inc83,342New0.44%$2 MNov 13, 2026
20Sumitomo Mitsui Trust Group, Inc.74,910New0.40%$1 MOct 29, 2026
21Amova Asset Management Americas, Inc.74,910New0.40%$1 MNov 13, 2026
22Northern Trust Corp74,721New0.39%$1 MNov 16, 2026
23UBS Group AG71,067New0.38%$1 MNov 10, 2026
24Vanguard Portfolio Management LLC67,039New0.35%$1 MNov 13, 2026
25Vanguard Fiduciary Trust Co64,267New0.34%$1 MNov 13, 2026
Show all 63: investors 26 to 63
Institutional investors 26 to 63 in Scribe Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Nuveen, LLC41,470New0.22%$1 MNov 10, 2026
27IQ EQ FUND MANAGEMENT (IRELAND) Ltd40,876New0.22%$1 MNov 13, 2026
28Longaeva Partners L.P.34,034New0.18%$1 MNov 16, 2026
29Charles Schwab Investment Management Inc31,644New0.17%$1 MNov 16, 2026
30Bank Of America Corp /de/27,589New0.15%$1 MNov 16, 2026
31Point72 Asset Management, L.P.22,771New0.12%$0 MNov 16, 2026
32Wells Fargo & Company/mn22,500New0.12%$0 MNov 16, 2026
33Goldman Sachs Group Inc21,635New0.11%$0 MNov 16, 2026
34Bank of New York Mellon Corp20,396New0.11%$0 MNov 5, 2026
35Focus Partners Wealth20,025New0.11%$0 MNov 12, 2026
36Susquehanna International Group, LLP13,641New0.07%$0 MNov 16, 2026
37Seven Grand Managers, LLC10,000New0.05%$0 MNov 16, 2026
38Rhumbline Advisers8,897New0.05%$0 MNov 10, 2026
39Morgan Stanley8,536New0.05%$0 MNov 13, 2026
40Deutsche Bank AG\8,269New0.04%$0 MNov 6, 2026
41Jpmorgan Chase & Co6,028New0.03%$0 MNov 12, 2026
42MetLife Investment Management, LLC5,814New0.03%$0 MNov 16, 2026
43Citigroup Inc4,742New0.03%$0 MNov 4, 2026
44MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.4,636New0.02%$0 MNov 16, 2026
45Kayne Anderson Rudnick Investment Management LLC4,195New0.02%$0 MNov 13, 2026
46Vanguard Global Advisers, LLC3,592New0.02%$0 MNov 13, 2026
47Tema Etfs LLC3,046New0.02%$0 MOct 16, 2026
48Strs Ohio2,600New0.01%$0 MOct 30, 2026
49BNP Paribas Financial Markets2,400New0.01%$0 MNov 12, 2026
50Police & Firemen's Retirement System of New Jersey2,289New0.01%$0 MNov 9, 2026
51Royal Bank Of Canada1,292New0.01%$0 MNov 16, 2026
52Tower Research Capital LLC (TRC)1,024New0.01%$0 MNov 16, 2026
53Osaic Holdings, Inc.1,000New0.01%$0 MNov 12, 2026
54Steward Partners Investment Advisory, LLC1,000New0.01%$0 MNov 13, 2026
55Ghisallo Capital Management LLC1,000New0.01%$0 MNov 16, 2026
56Legal & General Group Plc914New0.00%$0 MNov 16, 2026
57Ameritas Investment Partners, Inc.865New0.00%$0 MNov 13, 2026
58Russell Investments Group, Ltd.730New0.00%$0 MNov 6, 2026
59Sterling Capital Management LLC269New0.00%$0 MOct 22, 2026
60Allworth Financial LP218New0.00%$0 MNov 17, 2026
61California State Teachers Retirement System134New0.00%$0 MNov 13, 2026
62FMR LLC121New0.00%$0 MNov 10, 2026
63Jacobi Capital Management LLC25New0.00%$0 MNov 5, 2026

Mutual funds holding Scribe Therapeutics Inc.#

2 funds hold shares worth $10 M (about 2.6% of the company). Since their previous reports 2 added shares and 0 sold, buying $10 M net.
Mutual funds holding Scribe Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 ARK Genomic Revolution ETFARK Investment Management LLC352,097$7 M1.9%0.44%newJul 31, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.135,567$3 M0.72%0.23%newJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Scribe Therapeutics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$56.3 M
9 purchases, 6 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$56.3 M
open market only
Insiders on file
7
since
Scribe Therapeutics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Avoro Ventures LLCDirectorBuyindirect+7,905$18.25$144 K3.09 MForm 4
filed Orbimed Advisors LLCDirectorConversionindirect+348,825——348,825Form 4
filed AH Equity Partners Bio II, L.L.C.10% ownerConversionindirect+2.05 M——2.05 MForm 4
filed Jennifer A. Doudna10% ownerConversion+12,511——603,547Form 4
filed Carl L. GordonDirectorConversionindirect+348,825——348,825Form 4
filed AH Equity Partners Bio II, L.L.C.10% ownerConversionindirect+697,650——697,650Form 4
filed Orbimed Advisors LLCDirectorBuyindirect+1.00 M$15.00$15.0 M1.35 MForm 4
filed Carl L. GordonDirectorBuyindirect+1.00 M$15.00—1.35 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Scribe Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.7 M
4.01 days to cover
Shares sold short, last 7 reportsAll stocks →

IPO: priced at $15.00, raising $128.7M · IPO calendar

Fails to deliver

  • : 21,515 shares at $17.44
  • : 2,173 shares at $17.54
  • : 157 shares at $15.60
  • : 3,701 shares at $17.96
  • : 1,851 shares at $19.30

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Scribe Therapeutics Inc. scorecard#

Passes 0 of the 2 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 1
    • –P/E below its peers' medianNo P/E on file.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • –Earnings yield above the 10-year Treasury yieldNo P/E on file.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growthnot known
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitabilitynot known
    • –Profitable in the newest yearNo net income on file.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 1
    • ✗Short-term assets cover short-term liabilities1.0×Current ratio 0.97 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Events at Scribe Therapeutics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Bylaws or fiscal year changed 1 · Results announced 2

Scribe Therapeutics Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Scribe Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2021$100 MNo. 1$50 to $250 million19equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Scribe Therapeutics Inc.#

2 labor condition applications certified in fiscal 2025 for 2 positions, at a median wage of $147 K a year.

Certified, FY2025
2
#1,644 among companies on value.today
Worker positions
2
Median wage offered
$147 K
a year, full-time
Applications filed
2
Scribe Therapeutics Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Principal ScientistBioinformatics Scientists1$166 K
Scientist IBioinformatics Scientists1$127 K

Where: Alameda, CA 2

Scribe Therapeutics Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202522$147 K2
FY202466$135 K6
FY202322$125 K2
FY202233$133 K3
FY202111$87 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Scribe Therapeutics Inc.

How Scribe Therapeutics Inc. compares in Biotechnology

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Scribe Therapeutics Inc.🇺🇸$330 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Scribe Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Scribe Therapeutics Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Scribe Therapeutics Inc.? Suggest a correction